|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 肿瘤18F-FDG PET/MRI全身显像专家共识(德国)显示文摘PET/MRI一体机在2006年被首次提出可应用于临床;2010年,首台临床型PET/MRI一体机诞生。在20世纪早期,PET/CT和SPECT/CT一体机的广泛应用体现了融合显像的优势,为PET/MRI一体机的产生奠定了基础。目前,全球大约有150台全身PET/MRI一体机投入了临床应用,其中肿瘤显像是PET/MRI的主要应用领域之一。迄今为止,尽管PET/MRI临床应用在增加,但标准化的PET/MRI扫描方案还很少。因此,有必要制定患者检查和多中心研究都可遵循的标准化且一致性好的显像方案。该文总结了18F-脱氧葡萄糖(FDG)PET/MRI全身显像的患者就诊、检查准备、工作流程、显像方案以及报告书写等主要方面的专家共识,由长期使用PET、MRI和较早使用PET/MRI的相关资深专家制定。 | 王洋洋 杨光杰(译) 王振光(审校) Lale Umutlu Thomas Beyer Johannes Stefan Grueneisen Christoph Rischpler Harald H Quick Veit-Haibach Patrick Matthias Eiber Sandra Purz Gerald Antoch Sergios Gatidis Konstantin Nikolaou Jürgen FSchaefer IvoRausch Herrmann Ken K.Herrmann B.J.Krause S.O.Schoenberg L.Umutlu F.Anton G.Antoch M.Hacker M.Luster S.Neumann D.Vorwerk | 2020 | 中华核医学与分子影像杂志2020，40，9： | 1 |
| 2 | The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT显示文摘 | Robert Rosenberg Ken Herrmann Ralf Gertler Beat Künzli Markus Essler Florian Lordick Karen Becker Tibor Schuster Hans Geinitz Matthias Maak Markus Schwaiger J?rg-Rüdiger Siewert Bernd Krause | 2009 | International Journal of Colorectal Disease2009，，2： | 1 |
| 3 | 177Lu-PSMA放射性配体在前列腺癌治疗中的应用显示文摘利用前列腺特异膜抗原(PSMA)抑制剂进行177Lu-PSMA放射性配体治疗(RLT)是针对转移性去势抵抗性前列腺癌(mCRPC)患者的一种新型治疗模式。研究表明,该疗法行之有效且患者耐受性好。基于临床需求和现有研究依据,该疗法已在全球范围内的多个医疗中心付诸实施。该文对177Lu-PSMA的RLT的几个重要方面进行综述,包括患者分级分期、治疗方案、合并用药、患者随访等,旨在对参与RLT的医务工作者和mCRPC患者提供指导。 | 王帅亮(译) 杨卫东 汪静(审校) Wolfgang P. Fendler Kambiz Rahbar Ken Herrmann Clemens Kratochwil Matthias Eiber | 2019 | 中华核医学与分子影像杂志2019，39，10： | 1 |
| 4 | Irrigation of treated wastewater in Braunschweig,Germany:an option to remove pharmaceuticals and musk fragrances显示文摘 | Thomas A Ternies Matthias Bonerz Nadine Herrmann | | 0，，66： | 1 |
| 5 | The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT显示文摘 | Robert Rosenberg Ken Herrmann Ralf Gertler Beat Künzli Markus Essler Florian Lordick Karen Becker Tibor Schuster Hans Geinitz Matthias Maak Markus Schwaiger J?rg-Rüdiger Siewert Bernd Krause | 2009 | International Journal of Colorectal Disease2009，，： | 1 |
| 6 | Mechanism of action for leflunomide in rheumatoid arthritis显示文摘 | Robert I Fox Matthias L Herrmann | 1999 | Clin Immunol1999，93，3： | 1 |
| 7 | Nanosecond, kilovolt pulse generators显示文摘 | Ulrike Hahn Matthias Herrmann Frank Leipold | 2001 | Digest of Technical Papers2001，，2： | 1 |
| 8 | Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases显示文摘 | Matthias L Herrmann Schleyerbach R | 2000 | Immunopharmacology2000，47，23： | 1 |
| 9 | Nanosecond, kilovolt pulse generators显示文摘 | Ulrike Hahn Matthias Herrmann Frank Leipold | 2001 | Pulsed Power Plasma Science2001，，： | 1 |
| 10 | Determination of serum biomarkers in osteoarthritis patients:a previous interventional imaging study revisited显示文摘To evaluate in an interventional trial on knee osteoarthritis(OA) the level and change of two serum biomarkers and their correlation with imaging parameters.The previously reported interventional OA study(ClinicalTrials.gov:NCT00536302) identified a positive effect of collagen hydrolysate(CH) on cartilage morphology in patients with knee OA using delayed gadolinium enhanced magnetic resonance imaging(dGEMRIC).It was the objective in this research project to evaluate in an interventional clinical trial on knee OA the level and change of two serum biomarkers and their correlation with imaging parameters.In blood samples of study participants,we determined the concentration of procollagen type II N-terminal propeptide(PIIANP) and aggrecan chondroitin sulfate 846 epitope(CS846) at baseline(BL) and at the follow-up(FU) visits at 24 and 48 weeks.We measured the level and change of biomarker concentrations in both study groups,and the correlation of those changes with changes in dGEMRIC.For the biomarker PIIANP,we observed a significantly greater increase in the CH group(29.9%vs.1.2%at week 24,P =0.001).For CS846,the mean concentration was lower among the CH treated participants at 24 weeks(78%vs.96%,P= 0.045).Consistent correlations of changes in biomarkers PIIANP and CS846 with changes of the dGEMRIC score could not be observed.In this study,different changes per treatment group,CH and placebo were seen for dGEMRIC and PIIANP BL to 24 weeks FU,but only weak correlations between changes in dGEMRIC and biochemical markers. | Timothy McAlindon Eckart Bartnik Janina S.Ried Lenore Teichert Matthias Herrmann Klaus Flechsenhar | 2017 | The Journal of Biomedical Research2017，31，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员